Regular Article
A Low-Molecular-Weight Inhibitor against the Chemokine Receptor CXCR4: A Strong Anti-HIV Peptide T140

https://doi.org/10.1006/bbrc.1998.9871Get rights and content

Abstract

T22 ([Tyr5,12, Lys7]-polyphemusin II) is an 18-residue peptide amide, which has strong anti-HIV activity. T22 inhibits the T cell line-tropic (T-tropic) HIV-1 infection through its specific binding to a chemokine receptor CXCR4, which serves as a coreceptor for the entry of T-tropic HIV-1 strains. Herein, we report our finding of novel 14-residue CXCR4 inhibitors, T134 and T140, on the basis of the T22 structure. In the assays we examined, T140 showed the highest inhibitory activity against HIV-1 entry and the strongest inhibitory effect on the binding of an anti-CXCR4 monoclonal antibody (12G5) to CXCR4 among all the CXCR4 inhibitors that have been reported up to now.

References (40)

  • H. Choe et al.

    Cell

    (1996)
  • B.J. Doranz et al.

    Cell

    (1996)
  • M. Masuda et al.

    Biochem. Biophys. Res. Commun.

    (1992)
  • H. Tamamura et al.

    Biochim. Biophys. Acta

    (1993)
  • H. Tamamura et al.

    Bioorg. Med. Chem.

    (1998)
  • H. Tamamura et al.

    Bioorg. Med. Chem.

    (1998)
  • H. Tamamura et al.

    Biochim. Biophys. Acta

    (1996)
  • R.I. Connor et al.

    Virology

    (1995)
  • M.J. Endres et al.

    Cell

    (1996)
  • H. Tamamura et al.

    Bioorg. Med. Chem.

    (1998)
  • M. Balter

    Science

    (1996)
  • H. Mitsuya

    Exp. Med. (Tokyo)

    (1997)
  • Y. Feng et al.

    Science

    (1996)
  • H. Deng et al.

    Nature

    (1996)
  • T. Dragic et al.

    Nature

    (1996)
  • G. Alkhatib et al.

    Science

    (1996)
  • H. Nakashima et al.

    Antimicrob. Agents Chemother.

    (1992)
  • T. Murakami et al.

    J. Exp. Med.

    (1997)
  • T. Nagasawa et al.

    Proc. Natl. Acad. Sci. USA

    (1994)
  • Cited by (303)

    View all citing articles on Scopus
    1

    To whom correspondence should be addressed. Fax: 81-75-753-4570. E-mail:[email protected]/[email protected].

    View full text